Scientists hunt for clues to predict who will develop bone marrow cancer
NCT ID NCT07214324
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at people with early blood disorders (MGUS and smoldering myeloma) who are at risk of developing multiple myeloma, a type of bone marrow cancer. Researchers will use advanced genetic and immune testing on blood and bone marrow samples, along with mouth bacteria analysis, to find markers that signal disease progression. The goal is to improve risk prediction and guide future prevention strategies. The study is observational and does not test any new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to better ways to predict which patients with early blood disorders will develop multiple myeloma, enabling earlier monitoring or prevention.
What could go wrong
This is an early observational study with only 60 participants, so results may not apply broadly. It does not test any treatment, so direct patient benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Istituto Ortopedico Rizzoli IRCCS
ACTIVE_NOT_RECRUITINGBologna, Italy
-
S.C Ematologia - Azienda USL IRCCS di Reggio Emilia
RECRUITINGReggio Emilia, Italy
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
UO Ematologia Azienda Ospedaliero-Universitaria "Policlinico Rodolico San Marco"
ACTIVE_NOT_RECRUITINGCatania, Italy
-
UOC di Ematologia, Dipartimento di Oncologia, AOU Policlinico "Paolo Giaccone"
ACTIVE_NOT_RECRUITINGPalermo, Italy